This company listing is no longer active
このページの翻訳は実験的なもので、現在 開発中です。お待ちしております!
ProMIS Neurosciences 過去の業績
過去 基準チェック /06
ProMIS Neurosciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 32.1% annually. Revenues have been declining at an average rate of 8.3% per year.
主要情報
-21.7%
収益成長率
-4.0%
EPS成長率
Biotechs 業界の成長 | 51.1% |
収益成長率 | -8.3% |
株主資本利益率 | n/a |
ネット・マージン | n/a |
前回の決算情報 | 31 Mar 2023 |
最近の業績更新
Recent updates
収支内訳
ProMIS Neurosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
31 Mar 23 | 0 | -21 | 8 | 0 |
31 Dec 22 | 0 | -18 | 8 | 0 |
30 Sep 22 | 0 | -12 | 6 | 0 |
30 Jun 22 | 0 | -8 | 5 | 0 |
31 Mar 22 | 0 | -6 | 5 | 0 |
31 Dec 21 | 0 | -10 | 4 | 0 |
30 Sep 21 | 0 | -8 | 2 | 0 |
30 Jun 21 | 0 | -8 | 1 | 0 |
31 Mar 21 | 0 | -9 | 2 | 0 |
31 Dec 20 | 0 | -4 | 2 | 0 |
30 Sep 20 | 0 | -5 | 2 | 0 |
30 Jun 20 | 0 | -5 | 2 | 0 |
31 Mar 20 | 0 | -5 | 2 | 0 |
31 Dec 19 | 0 | -6 | 2 | 0 |
30 Sep 19 | 0 | -7 | 2 | 0 |
30 Jun 19 | 0 | -8 | 2 | 0 |
31 Mar 19 | 0 | -8 | 2 | 0 |
31 Dec 18 | 0 | -7 | 2 | 0 |
30 Sep 18 | 0 | -6 | 2 | 0 |
30 Jun 18 | 0 | -5 | 2 | 0 |
31 Mar 18 | 0 | -5 | 2 | 0 |
31 Dec 17 | 0 | -5 | 2 | 0 |
30 Sep 17 | 0 | -5 | 2 | 0 |
30 Jun 17 | 0 | -4 | 2 | 0 |
31 Mar 17 | 0 | -3 | 1 | 0 |
31 Dec 16 | 0 | -3 | 1 | 0 |
30 Sep 16 | 0 | -2 | 1 | 0 |
30 Jun 16 | 0 | -2 | 1 | 0 |
31 Mar 16 | 0 | -2 | 1 | 0 |
31 Dec 15 | 0 | -2 | 1 | 0 |
30 Sep 15 | 0 | -1 | 1 | 0 |
30 Jun 15 | 0 | -2 | 1 | 0 |
31 Mar 15 | 0 | -2 | 1 | 0 |
31 Dec 14 | 0 | -2 | 1 | 0 |
30 Sep 14 | 0 | -3 | 1 | 0 |
30 Jun 14 | 0 | -2 | 1 | 0 |
31 Mar 14 | 0 | -2 | 1 | 0 |
31 Dec 13 | 0 | -2 | 1 | -1 |
30 Sep 13 | 0 | -2 | 1 | -1 |
30 Jun 13 | 0 | -2 | 1 | 0 |
31 Mar 13 | 0 | -2 | 1 | 0 |
31 Dec 12 | 0 | -2 | 1 | 2 |
30 Sep 12 | 0 | -3 | 1 | 2 |
質の高い収益: PMN is currently unprofitable.
利益率の向上: PMN is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: PMN is unprofitable, and losses have increased over the past 5 years at a rate of 21.7% per year.
成長の加速: Unable to compare PMN's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: PMN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
株主資本利益率
高いROE: PMN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.